Hematopoietic Stem Cell Transplantation Market - A Global and Regional Analysis: Focus on Transplant Type, Indication, Country and Region - Analysis and Forecast, 2025-2035

June 2026 | - | ID: H464EDF07D26EN
BIS Research Inc.

Abstracts

Hematopoietic stem cell transplantation involves infusing stem cells to re-establish bone marrow function in patients whose bone marrow or immune systems are damaged or defective. The therapy is commonly used to treat leukaemia, lymphoma, multiple myeloma, and several non-malignant blood disorders. There are two principal approaches: autologous transplantation, which uses the patient’s own stem cells, and allogeneic transplantation, which uses donor stem cells from a related or unrelated match.

Advances in donor registries, conditioning regimens, and graft manipulation have enhanced transplant outcomes and expanded patient eligibility. Moreover, advancements in immunogenetics and cellular engineering are enabling better prevention and management of transplant-related complications, such as graft-versus-host disease. The integration of artificial intelligence and predictive modelling in donor-recipient matching is also optimising treatment decisions and improving long-term survival outcomes.

Market Lifecycle Stage

The global hematopoietic stem cell transplantation market is in an evolving growth phase characterised by increasing adoption, technological advancements, and expanding clinical applications. Autologous transplantation remains a dominant therapy for multiple myeloma and certain lymphomas due to lower immune-related risks and high response rates. However, allogeneic transplantation continues to grow as a curative option for acute leukaemia, bone marrow failure syndromes, and congenital immune disorders.

The introduction of reduced-intensity conditioning regimens has allowed transplantation in older or high-risk patients who were previously ineligible. Additionally, advances in cord blood transplantation, haploidentical donor transplants, and ex vivo graft manipulation technologies are broadening access to suitable donors.

Global regulatory bodies, including the U.S. Food and Drug Administration and the European Medicines Agency, are encouraging innovation in stem cell therapy by supporting expedited approval pathways and adaptive clinical trial designs. Emerging regions such as Asia-Pacific, the Middle East, and Latin America are expanding their transplant networks through government and private-sector investments, making curative therapy more accessible to patients.

Market Segmentation:

Segmentation 1: By Transplant Type

• Autologous transplants
• Allogeneic transplants

Autologous transplants remain a cornerstone for hematologic malignancies such as multiple myeloma and certain lymphomas, offering reduced immune complications and enabling high-intensity conditioning regimens, while allogeneic transplants are preferred for acute leukaemia and non-malignant disorders due to the graft-versus-leukaemia effect, with innovations in donor matching, stem cell sources, and post-transplant immunosuppression driving adoption.

Segmentation 2: By Indication

• Acute Myeloid Leukaemia
• Acute Lymphoblastic Leukaemia
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• Multiple Myeloma
• Other Non-Malignant Disorders

By indication, Hematopoietic Stem Cell Transplantation is widely applied for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), with advances in molecular diagnostics and conditioning improving outcomes; for Hodgkin and non-Hodgkin lymphomas, both autologous and allogeneic transplants are used alongside emerging therapies like CAR-T cells. Multiple myeloma primarily relies on autologous Hematopoietic Stem Cell Transplantation combined with novel agents, while other non-malignant disorders—including aplastic anaemia, thalassemia, sickle cell disease, and immune deficiencies—are increasingly treated with allogeneic transplants supported by enhanced donor registries and reduced-intensity conditioning protocols.

Segmentation 3: By Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

North America leads the global Hematopoietic Stem Cell Transplantation market due to advanced healthcare infrastructure, established transplant centres, robust reimbursement policies, and strong R&D in stem cell therapies. Europe follows closely, supported by well-established clinical networks, comprehensive donor registries, and ongoing research collaborations. Asia-Pacific represents the fastest-growing region, driven by increasing prevalence of hematologic disorders, expanding healthcare access, and growing awareness of curative stem cell therapies. The Rest of the World, including Latin America, the Middle East, and Africa, is emerging as a potential growth area, with rising investments in transplant infrastructure, improved diagnostic capabilities, and greater adoption of advanced transplantation protocols.

Demand – Drivers and Limitations

Demand drivers for the global hematopoietic stem cell transplantation market:

• Rising awareness and adoption of hematopoietic stem cell transplantation as a curative therapy
• Technological advancements in donor matching, graft manipulation, and post-transplant care

Limitations for the global hematopoietic stem cell transplantation market:

• Risk of complications such as graft-versus-host disease, infections, and relapse post-transplant
• High cost of the therapy

How can this report add value to an organisation?

Product/Innovation: The report provides comprehensive insights into the evolving technological and clinical landscape of hematopoietic stem cell transplantation. It explores innovations in graft engineering, donor selection algorithms, and post-transplant immunomodulatory therapies. This enables research and development teams to identify emerging collaboration opportunities and focus areas for pipeline expansion.

Growth/Marketing: By analysing regional adoption patterns, procedure volumes, and emerging therapeutic indications, the report supports strategic expansion and market entry planning for transplant centres, biotechnology firms, and medical device manufacturers.

Competitive: Through company profiling, pipeline analysis, and regulatory tracking, the report enables stakeholders to benchmark competitive positioning, understand innovation trends, and anticipate market shifts in the hematopoietic stem cell transplantation landscape.

Key Market Players and Competitive Landscape

This report presents an in-depth competitive analysis of the major participants in the global hematopoietic stem cell transplantation market. Companies are evaluated based on therapeutic portfolios, technological innovations, market presence, and strategic collaborations. Key players include:

• Actinium Pharmaceuticals, Inc.
• BioLineRx Ltd.

These organisations are actively involved in developing next-generation hematopoietic stem cell transplantation therapies, supportive treatments for transplant patients, and cell-based immunotherapies. The competitive benchmarking section highlights research and development investments, clinical trial pipelines, partnerships with academic institutions, and regulatory approvals. Company profiles provide insights into therapeutic offerings, pipeline progress, clinical outcomes, key personnel, and analyst perspectives—enabling stakeholders to assess market positioning and strategic opportunities in the global hematopoietic stem cell transplantation market.

Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.

This report will be delivered in 7-10 working days.

Contents

Executive Summary
Scope of Study
Definition
Inclusion and Exclusion Criteria

1. GLOBAL HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET: INDUSTRY OUTLOOK

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
  1.2.1 U.S.
  1.2.2 EU
    1.2.2.1 Germany
    1.2.2.2 France
  1.2.3 Rest-of-the-World
1.3 Market Trends
1.4 Clinical Trial Analysis
1.5 Regulatory Landscape Analysis
  1.5.1 Legal Requirement and Framework in U.S.
  1.5.2 Legal Requirement and Framework in E.U.
  1.5.3 Legal Requirement and Framework in Asia-Pacific
  1.5.4 Legal Requirement and Framework in Rest-of-the-World
1.6 Market Dynamics
  1.6.1 Impact Analysis
  1.6.2 Market Drivers
  1.6.3 Market Restraints
  1.6.4 Market Opportunities

2. GLOBAL HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET, BY TRANSPLANT TYPE, $MILLION, 2024-2035

2.1 Autologous Transplant
2.2 Allogeneic Transplant

3. GLOBAL HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET, BY INDICATION, $MILLION, 2024-2035

3.1 Acute Myeloid Leukemia
3.2 Acute Lymphoblastic Leukemia
3.3 Hodgkin Lymphoma
3.4 Non-Hodgkin Lymphoma
3.5 Multiple Myeloma
3.6 Other Non-Malignant Disorders

4. GLOBAL HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET, BY REGION, $MILLION, 2024-2035

4.1 North America
  4.1.1 Key Findings
  4.1.2 Market Dynamics
  4.1.3 Market Sizing and Forecast
    4.1.3.1 North America Hematopoietic Stem Cell Transplantation Market (by Country)
      4.1.3.1.1 U.S.
      4.1.3.1.2 Canada
4.2 Europe
  4.2.1 Key Findings
  4.2.2 Market Dynamics
  4.2.3 Market Sizing and Forecast
    4.2.3.1 Europe Hematopoietic Stem Cell Transplantation Market (by Country)
      4.2.3.1.1 Germany
      4.2.3.1.2 France
      4.2.3.1.3 Italy
      4.2.3.1.4 Spain
      4.2.3.1.5 U.K.
      4.2.3.1.6 Rest-of-Europe
4.3 Asia-Pacific
  4.3.1 Key Findings
  4.3.2 Market Dynamics
  4.3.3 Market Sizing and Forecast
    4.3.3.1 Asia-Pacific Hematopoietic Stem Cell Transplantation Market (by Country)
      4.3.3.1.1 Japan
      4.3.3.1.2 Rest-of-Asia-Pacific
4.4 Rest-of-the-World
  4.4.1 Key Findings
  4.4.2 Market Dynamics
  4.4.3 Market Sizing and Forecast

5. GLOBAL HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET: COMPETITIVE BENCHMARKING AND COMPANY PROFILES

5.1 Competitive Benchmarking
5.2 Competitive Landscape
  5.2.1 Key Strategies and Developments by Company
    5.2.1.1 Funding Activities
    5.2.1.2 Mergers and Acquisitions
    5.2.1.3 Regulatory Approvals
    5.2.1.4 Partnerships, Collaborations, and Business Expansions
  5.2.2 Key Developments Analysis
5.3 Company Profiles
  5.3.1 Actinium Pharmaceuticals, Inc.
    5.3.1.1 Company Overview
    5.3.1.2 Product Portfolio
    5.3.1.3 Target Customers/End Users
    5.3.1.4 Key Personnel
    5.3.1.5 Analyst View
  5.3.2 BioLineRx Ltd.
    5.3.2.1 Company Overview
    5.3.2.2 Product Portfolio
    5.3.2.3 Target Customers / End Users
    5.3.2.4 Key Personnel
    5.3.2.5 Analyst View
  5.3.3 Others

6. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Hematopoietic Stem Cell Transplantation Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Hematopoietic Stem Cell Transplantation Market, 2024 and 2035
Figure: Global Hematopoietic Stem Cell Transplantation Market Key Trends, Impact Analysis, 2024-2035
Figure: North America Hematopoietic Stem Cell Transplantation Market, $Million, 2024-2035
Figure: Europe Hematopoietic Stem Cell Transplantation Market, $Million, 2024-2035
Figure: Asia-Pacific Hematopoietic Stem Cell Transplantation Market, $Million, 2024-2035
Figure: Rest-of-the-World Hematopoietic Stem Cell Transplantation Market, $Million, 2024-2035

List Of Tables

LIST OF TABLES

Table: Market Snapshot
Table: Market Dynamics
Table: Global Hematopoietic Stem Cell Transplantation Market (by Transplant Type), $Million, 2024-2035
Table: Global Hematopoietic Stem Cell Transplantation Market (by Indication), $Million, 2024-2035
Table: Global Hematopoietic Stem Cell Transplantation Market (by Region), $Million, 2024-2035